CDCRX
Price
$11.70
Change
+$0.03 (+0.26%)
Updated
Jul 31 closing price
Net Assets
25.27M
FSMAX
Price
$114.13
Change
-$0.47 (-0.41%)
Updated
Jul 31 closing price
Net Assets
40.08B
Interact to see
Advertisement

CDCRX vs FSMAX

CDCRX vs FSMAX Comparison Chart in %
View a ticker or compare two or three
VS
CDCRX vs. FSMAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDCRX is a Buy and FSMAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FSMAX has more cash in the bank: 40.1B vs. CDCRX (25.3M). FSMAX pays higher dividends than CDCRX: FSMAX (0.50) vs CDCRX (0.00). CDCRX was incepted earlier than FSMAX: CDCRX (15 years) vs FSMAX (15 years). CDCRX (2.67) is less costly to investors than FSMAX (0.04). CDCRX is a more actively managed with annual turnover of: 27.00 vs. FSMAX (23.00). FSMAX has a lower initial minimum investment than CDCRX: FSMAX (0) vs CDCRX (1000). FSMAX annual gain was more profitable for investors over the last year : 20.57 vs. CDCRX (0.60). FSMAX return over 5 years is better than : 33.18 vs. CDCRX (-14.60).
CDCRXFSMAXCDCRX / FSMAX
Total Expense Ratio1.950.045,571%
Annual Report Gross Expense Ratio2.670.047,629%
Fund Existence15 years15 years-
Gain YTD6.26713.37047%
Front LoadN/AN/A-
Min. Initial Investment10000-
Min. Initial Investment IRAN/AN/A-
Net Assets25.3M40.1B0%
Annual Yield % from dividends0.000.50-
Returns for 1 year0.6020.573%
Returns for 3 years-1.8555.83-3%
Returns for 5 years-14.6033.18-44%
Returns for 10 years-4.96133.82-4%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYNCX137.921.38
+1.01%
Rydex Nova C
AMGIX44.590.24
+0.54%
American Century Disciplined Value I
FEQNX15.880.08
+0.51%
Fidelity Advisor Hedged Equity M
ISTIX110.600.29
+0.26%
Nomura Science and Technology I
AIOOX12.23-0.01
-0.08%
Aristotle/Saul Global Equity I-2